Citigroup
NKTR icon

Citigroup’s Nektar Therapeutics NKTR Stock Holding History

Citigroup’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,353
Closed -$109K – 6512
2022
Q1 		$109K Buy
+1,353
New +$200K ﹤0.01% 4370
2021
Q1 		– Sell
-2,733
Closed -$697K – 7021
2020
Q4 		$697K Buy
2,733
+1,380
+102% +$357K ﹤0.01% 3912
2020
Q3 		$337K Sell
1,353
-1,780
-57% -$560K ﹤0.01% 4197
2020
Q2 		$1.09M Sell
3,133
-334
-10% -$104K ﹤0.01% 3472
2020
Q1 		$928K Sell
3,467
-273
-7% -$84.4K ﹤0.01% 3252
2019
Q4 		$1.21M Sell
3,740
-167
-4% -$48.4K ﹤0.01% 3562
2019
Q3 		$1.07M Buy
3,907
+1,967
+101% +$721K ﹤0.01% 3575
2019
Q2 		$1.03M Buy
1,940
+833
+75% +$418K ﹤0.01% 3582
2019
Q1 		$558K Sell
1,107
-2,520
-69% -$1.49M ﹤0.01% 4071
2018
Q4 		$1.79M Buy
3,627
+1,727
+91% +$1.04M ﹤0.01% 2775
2018
Q3 		$1.74M Sell
1,900
-3,853
-67% -$3.29M ﹤0.01% 2892
2018
Q2 		$4.21M Buy
5,753
+5,320
+1,229% +$6.13M ﹤0.01% 2004
2018
Q1 		$691K Sell
433
-767
-64% -$988K ﹤0.01% 3642
2017
Q4 		$1.07M Buy
1,200
+573
+91% +$339K ﹤0.01% 3269
2017
Q3 		$226K Buy
627
+227
+57% +$71K ﹤0.01% 4886
2017
Q2 		$117K Sell
400
-13
-3% -$3.76K ﹤0.01% 5233
2017
Q1 		$146K Sell
413
-374
-48% -$84.1K ﹤0.01% 4912
2016
Q4 		$145K Sell
787
-3,246
-80% -$660K ﹤0.01% 5543
2016
Q3 		$1.04M Buy
4,033
+3,073
+320% +$791K ﹤0.01% 3173
2016
Q2 		$205K Buy
960
+513
+115% +$115K ﹤0.01% 4480
2016
Q1 		$92K Buy
447
+280
+168% +$53.8K ﹤0.01% 5722
2015
Q4 		$42K Buy
+167
New +$34.3K ﹤0.01% 6060
2015
Q3 		– Sell
-1,333
Closed -$250K – 7590
2015
Q2 		$250K Buy
+1,333
New +$229K ﹤0.01% 4263
2013
Q4 		– Sell
-1,840
Closed -$288K – 7091
2013
Q3 		$288K Buy
+1,840
New +$340K ﹤0.01% 3861

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Citigroup's NKTR Position: Q1 2026 in Review

Citigroup reduced its Nektar Therapeutics (NKTR) stake by 30% in Q1 2026, selling an estimated $611K and leaving 25,048 shares worth $1.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2728.

Citigroup first reported a position in NKTR in Q2 2013 and has held it in 52 quarters since. The position peaked at $5.47M in Q3 2018. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Citigroup held 25,048 shares of Nektar Therapeutics worth $1.8M as of Q1 2026.
  • Citigroup sold 10,729 Nektar Therapeutics shares in Q1 2026, an estimated $611K.
  • Nektar Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #2728 holding.
  • Citigroup first reported a position in Nektar Therapeutics in Q2 2013 and has held it in 52 quarters since.
  • Citigroup's Nektar Therapeutics position peaked at $5.47M in Q3 2018.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.